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Abstract To determine whether there is a direct corre-
lation between the concentration of type II collagen frag-
ment HELIX-II in synovial fluid and the severity of
cartilage damage at the knee joint, 83 patients who had
undergone knee arthroscopy or total knee replacement
were enrolled in this study (49% women, mean ± SD age
49.5 ± 19). The content of HELIX-II in the synovial fluid
samples was measured by enzyme-linked immunosorbent
assay (ELISA). Cartilage damage at the knee joint was
classified during arthroscopy or direct surgical observation,
using the Outerbridge cartilage damage scoring system.
The maximum damage score was defined as the highest
score among the six areas of the knee joint, and the
cumulative score was defined as the sum of the scores of
the six areas of the knee joint. The intra-assay and inter-
assay variations of the HELIX-II ELISA were lower than
13 and 15%, respectively. The level of HELIX-II in the
severely damaged cartilage groups (cumulative scores =
11–24 or maximum score = 2–4) was much higher than
in the slightly damaged cartilage groups (cumulative
scores = 0–10 or maximum score = 0–1). The level of
HELIX-II in cartilage from severely damaged cartilage
groups was significantly higher than in the slightly dam-
aged groups, but no significant difference was detected in
the level of HELIX-II among the severely damaged carti-
lage sub-groups. There was a significant correlation
between the HELIX-II concentration in the synovial fluid
and the cumulative (r = 0.807) and maximum scores
(r = 0.794). Thus, elevated HELIX-II level is correlated
with early cartilage lesions, but does not have the sensi-
tivity to predict the progression of severity of cartilage
damage in the knee joint.
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Cartilage damage  Biomarker
Introduction
Osteoarthritis (OA) is the most common cause of joint pain
and disability in the world and is characterized by the
progressive damage of articular cartilage [1, 2]. Early
diagnosis is crucial for the prevention of and treatment for
OA. Currently, plain X-rays have been the primary imag-
ing method used to confirm the diagnosis of OA (when an
X ray shows narrowed joint space due to cartilage loss),
stage its severity, and follow its progression. Unfortu-
nately, the severity of radiographic findings does not cor-
relate well with the severity of symptoms, nor with
functional disability [3, 4]. These shortcomings limit the
use of radiography both as a diagnostic tool and as a tool
for ongoing assessment of disease progression. With the
use of sensitive assays to recognize biomarkers in body
fluids, researchers could identify early signs of disease and
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standardize the measures of progression, which could then
increase the predictive power needed for clinical trials of
new treatments [5]. As the alteration in cartilage matrix
turnover occurs at the early stage of the disease, it is of great
importance to find the biomarkers for early diagnosis of OA.
During the biological turnover of cartilage, some
metabolites are released into the serum and synovial fluid
[6]. In the case of damage or trauma, the damaged cartilage
cells will also release lysosomal enzymes and collagenase,
which can lead to the degradation of type II collagen [7–9].
Because these metabolites and degradation products
change rapidly and dynamically with cartilage damage,
they could be used as specific biomarkers reflecting alter-
ations in the metabolism of cartilage [10–12].
Type II collagen is the main extracellular matrix protein
in hyaline articular cartilage. Degradation of type II col-
lagen is one of the metabolism alterations that take place
with cartilage damage. Measuring type II collagen metab-
olites in the fluid surrounding an articular joint would
therefore be a specific indicator of cartilage degradation at
that joint. One of such metabolites is type II collagen
helical peptide (HELIX-II), a molecule originating from
the helical region of type II collagen.
Several studies have demonstrated that the presence of
HELIX-II in serum or urine samples is positively associ-
ated with cartilage damage [13–15], but there is no direct
evidence to demonstrate this relationship. In this study, we
measured the level of HELIX-II in the knee joint’s synovial
fluid by ELISA, identified cartilage damage by arthro-
scopic findings, and classified it using the Outerbridge
scoring system. We found that the level of HELIX-II in the
synovial fluid from the knee joint correlates with early
lesions in associated knee’s articular cartilage, but it is not




The study enrolled 83 patients (42 men and 41 women)
with an average age of 49.5 years (49.5 ± 19). Among this
patient cohort, 42 received total knee replacement because
of osteoarthritis and 41 underwent arthroscopy because of
meniscus injury (n = 25), anterior or posterior cruciate
ligament injury (n = 14), loose body (n = 1), or patellar
dislocation (n = 1). Patients who had inflammatory joint
disease, acute major trauma, malignant tumors, or abnor-
mal renal and liver function were excluded from the study.
Patients who took corticosteroid treatment within the
3 months preceding surgery were also excluded from the
study.
Collection and storage of synovial fluid
A volume of 0.5–5 ml of synovial fluid was aspirated from
the knee joint just before total knee replacement or
arthroscopy. The synovial fluid was immediately centri-
fuged for 15 min at 3,000 rpm to remove particulate
material and any clots, and the supernatants were aliquoted,
rapidly frozen, and stored at -70C.
Evaluation of cartilage damage
Articular cartilage lesions were evaluated during arthros-
copy or via direct surgical observation, using the Outer-
bridge scoring system [19]. The absence of morphological
changes in the articular cartilage is regarded as 0 points in
the Outerbridge scoring system, and softened or swollen
articular cartilage is given 1 point. Once fissures smaller
than 1.5 cm appear on the articular cartilage surface, a
score of 2 points is given, while fissures larger that
1.5 cm merit a score of 3 points. When cartilage flakes
are detached from the articular surface, and the sub-
chondral bones are exposed, the Outerbridge score is 4
points [19].
Each of the six regions of the knee cartilage (i.e.,
patellar, femoral groove, medial femoral condyle, lateral
femoral condyle, medial tibial plateau, and lateral tibial
plateau) was given an Outerbridge score (Fig. 1). The
highest score recorded within one knee joint was defined as
the maximum score, and the addition of all six scores
within one knee joint was defined as the cumulative score.
Therefore, the highest possible maximum and cumulative
scores were 4 and 24, respectively.
Fig. 1 Lesion of knee articular cartilage evaluated by arthroscopy
with Outerbridge score system. 0 points no morphological changes in
the cartilage, 1 point cartilage softened or swollen, 2 points fissures
forming or already formed, but less than 1.5 cm, 3 points fissures
larger than 1.5 cm, 4 points subchondral bone exposed or cartilage
flakes detached
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Measurement of synovial HELIX-II
Synovial fluid HELIX-II content was measured using a
competitive polyclonal antibody–based ELISA (enzyme-
linked immunosorbent assay) kit (Rongweida Corporation,
Shanghai, China). After thawed to room temperature, all
samples were diluted at a ratio of 1:1; 50 ul of the diluted
sample and 50 ul of biotinylated anti-HELIX-II antibody
were then added to each well of a 96-well plate. After 1 h
of incubation at 37C, the wells were drained and washed 3
times with washing buffer; 80 ul of streptavidin-HRP
solution was then added to the wells, and the plate was
incubated for 30 min at 37C, and 50 ul of the kit’s Sub-
strate A and Substrate B was added to each well, followed
by incubation for 10 min at 37C before the reaction was
stopped by 50 ul of H2SO4. The absorbance at each well
was read by a spectrophotometer (The Packard Fluoro-
Count BF10000) at 450 nm wavelength. All samples were
measured as triplets, and the average reading was recorded.
Statistical analyses
All data are expressed as mean ± SD and analyzed using
SPSS 13.0 software (SPSS Inc, Chicago, IL). Student’s
T test was used for paired group comparisons, and one-way
ANOVA was used for inter-group comparisons. Nonpara-
metric Spearman’s rank correlation coefficient was used
for correlation analysis. P values less than 0.05 were
considered statistically significant.
Results
HELIX-II concentration in synovial fluid
was dependent on cartilage damage as determined
by the accumulative Outerbridge score
We found that the 83 patients could be divided into two
sub-population groups based on their cumulative Outer-
bridge score and their concentration of HELIX-II in
synovial fluid (Fig. 2). Thirty-five patients had cumulative
Outerbridge score less than 10, and these will be referred to
as the ‘‘slightly damaged cartilage’’ group. The remaining
48 patients had cumulative Outerbridge scores higher than
10 and will be referred to as the ‘‘severely damaged car-
tilage’’ group. The analysis showed that the HELIX-II
content in the synovial fluid of the patients from the
severely damaged cartilage group (1.11 ± 0.23 nmol/l)
was much higher than that of the slightly damaged cartilage
group (0.54 ± 0.19 nmol/l), and this difference was sta-
tistically significant (P \ 0.0001). A significant correlation
was found between the HELIX-II concentration in synovial
fluid and the cumulative scores (r = 0.807).
HELIX-II concentrations in synovial fluid were
correlated with cartilage damage as determined
by the maximum Outerbridge score
We found that the 83 cases could also be divided into 5
groups based on their maximum Outerbridge score. Only a
relatively small amount of HELIX-II was found in the
synovial fluid of knee joints with maximum Outerbridge
scores between 0 and 1 (slightly damaged cartilage
groups). The average HELIX-II concentration in synovial
fluid from the joints with a maximum Outerbridge score of
0 was 0.51 ± 0.22 nmol/l, and for those with a maximum
Outerbridge score of 1, it was 0.56 ± 0.15 nmol/l. There
was no significant difference detected in the synovial
fluid’s HELIX-II concentration of knee joints with a
maximum Outerbridge score of 0 and 1 (P [ 0.386).
However, the mean concentration of HELIX-II in the
synovial fluid increased dramatically in knees with Outer-
bridge scores 2–4 (severely damaged cartilage groups),
when compared with the slightly damaged cartilage groups
(P \ 0.0001). Maximum Outerbridge scores of 2, 3, and 4
were associated with mean HELIX-II concentrations of
0.97 ± 0.16, 1.06 ± 0.15, and 1.16 ± 0.26 nmol/l,
respectively (Fig. 3). A significant correlation was found
between the HELIX-II concentration in synovial fluid and
the maximum scores (r = 0.794) (Fig. 3).
The average content of HELIX-II in the severely dam-
aged cartilage group was 1.10 ± 0.23 nmol/l, which was
much higher than that in the slightly damage group, which
had 0.53 ± 0.19 nmol/l (P \ 0.0001). This suggests that
the concentration of synovial HELIX-II increases with
cartilage damage. Interestingly, inter-group comparisons
Fig. 2 The level of HELIX-II directly correlates with the cumulative
Outerbridge score. Mean concentrations of HELIX-II in the synovial
fluid significantly increased in the severely damaged cartilage group
(cumulative Outerbridge score 11–24) in comparison with the slightly
damaged cartilage group (cumulative Outerbridge score 1–10). There
was a significant correlation (r = 0.807) between the HELIX-II
concentration in synovial fluid and the articular cartilage cumulative
Outerbridge score
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did not detect significant differences in the HELIX-II
content among the severely damaged cartilage sub-groups
(Maximum Outerbridge scores 2, 3 and 4) (Fig. 3),
although there was an increasing trend. The mean con-
centration of HELIX-II only increased by 7.8% in the
maximum score 3 sub-group as compared to the maximum
score 2 sub-group (P = 0.2596). The mean concentration
increased by 8.6% in the maximum score 4 sub-group
relative to the maximum score 3 sub-group (P = 0.2279)
(Fig. 3).
Discussion
Unlike most tissues in the body, articular cartilage is an
avascular tissue with poor capacity for self-repair. Most
articular cartilage injuries are maintained for years and can
eventually lead to further damage. Therefore, early detec-
tion would be essential for the diagnosis, treatment, and
prevention of cartilage damage. Radiographic assessment
of joint space narrowing (an indicator of cartilage loss) is
the only validated measure of OA progression; however, it
is unable to detect early cartilage damage, nor has it been
shown to correlate with symptoms or functional disability
[3, 4, 16]. Assays that recognize specific biomarkers of
cartilage metabolism in body fluids could potentially be
used to detect early cartilage damage.
Type II collagen is the main extracellular matrix protein
of hyaline articular cartilage. The metabolites or degrada-
tion products of type II collagen could be used as
biomarkers to indicate the alterations in the metabolism of
articular cartilage [2, 10–12, 17]. Most available studies
report using serum or urine samples for the detection of
biomarkers of articular cartilage degradation [13–15]. As
type II collagen is not only resident in the articular carti-
lage, but also in other tissues such as nucleus of interver-
tebral disks, the levels of its metabolites or degradation
products in serum frequently do not correlate with struc-
tural changes and may not accurately reflect changes on the
articular cartilage [18]. The synovial fluid exists in the
cavity of joints, where it provides internal nutrition to the
articular cartilage. Theoretically, biomarkers in the syno-
vial fluid of joints affected with OA could directly reflect
the pathological changes in articular cartilage with less
interference factors compared with serum or urine.
The Outerbridge scoring system has been used to eval-
uate cartilage damage for a long time. A recent study
demonstrated that orthopedic surgeons can accurately
grade chondral lesions of the knee with the Outerbridge
classification [19]. It is a morphological scoring system that
directly reflects the changes in articular cartilage. In this
study, we found that HELIX-II concentrations in synovial
fluid change with cartilage damage. The content of HELIX-
II in the knee synovial fluid was low when the knee joint’s
cartilage surface was intact. The content of HELIX-II in
the knee synovial fluid increased once cartilage damage
occurred. This suggested that the synovial concentration of
HELIX-II could be used as a biomarker for early damage
of articular cartilage. Statistical analysis indicates that the
synovial HELIX-II levels in knee joint are directly corre-
lated with both Outerbridge cumulative scores and maxi-
mum scores.
Our study did not find a significant difference in the
synovial HELIX-II level between Outerbridge scores 0 and
1 (slightly damaged cartilage), which indicates that the
level of the synovial HELIX-II does not change for an
intact cartilage surface. Surprisingly, we found no signifi-
cant difference in the HELIX-II levels among the severely
damaged cartilage sub-groups (Outerbridge scores of 2, 3,
and 4 points), but we did find a significant difference
between the slightly damaged and severely damaged car-
tilage groups. As the Outerbridge score of 1 only refers to
softening and swelling of articular cartilage, while Outer-
bridge scores between 2 and 4 points indicate the rupture of
the cartilage surface, this finding implies that once the
surface of cartilage is fissured, the levels of HELIX-II in
the synovial fluid increase sharply. The detailed mecha-
nism remains unclear. One of the possible reasons is that
the intact surface of the articular cartilage may have
worked as a barrier for the release of collagen metabolites,
and that HELIX-II is only released into the synovial fluid
when fissures form on the cartilage surface, or flakes are
detached from the surface.
Fig. 3 The level of HELIX-II directly correlated with the maximum
Outerbridge score. Mean concentrations of HELIX-II in the synovial
fluid were significantly elevated between the slightly cartilage
damage group (maximum Outerbridge scores 0–1) and the severely
damaged cartilage group (maximum Outerbridge scores 2–4). How-
ever, there was no significance difference in HELIX-II concentration
among the severely damaged cartilage sub-groups (maximum Outer-
bridge score 2–4). There was a significant correlation (r = 0.794)
between the HELIX-II concentration in synovial fluid and the
articular cartilage maximum Outerbridge score
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There are several possible explanations for the absence
of differences in the synovial HELIX-II levels among
Outerbridge 2-, 3-, and 4-point sub-groups. One of the
possible explanations is that there is less type II collagen to
be degenerated and released into synovial fluid when the
cartilage damage becomes more severe and cartilage is
lost. The second possible explanation may be different
enzymatic pathway activities at the different stages of
cartilage degradation. A recent study indicated that the type
II fragments Helix-II and CTX-II are generated in part by
different enzymatic pathways including cathepsins and
matrix metalloproteases [9]. It would be interesting to
explore whether the observations in this study are due to a
different enzymatic activity at the different stages of car-
tilage damage.
In conclusion, the level of the HELIX-II in the knee
synovial fluid could be used as an early biomarker to reflect
cartilage damage, but cannot predict the severity and pro-
gression of knee articular cartilage damage.
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